Abstract: Abnormal high expression of Histone deacetylase(HDAC) promotes malignant proliferation of many kinds of tumor and has been identified as a new target for anti-triple negative breast cancer (TNBC) therapy. In view of the important role of HDACs played in tumorigenesis, a variety of HDAC inhibitors have been developed and widely used in basic research and clinical treatment of cancer. This paper reviewed the latest research progress of HDAC promote TNBC generation and the development and application of HDAC inhibitor in anti-TNBC therapy.

Key words: histone deacetylase, triple negative breast cancer, histone deacetylase inhibitor